Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Head Neck Pathol ; 9(3): 360-8, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25563452

ABSTRACT

Spindle cell carcinoma (SpCC) is an uncommon head and neck squamous cell carcinoma (SCC) variant consisting of spindled and/or pleomorphic cells with epithelial differentiation. Epidermal growth factor receptor (EGFR) is expressed by >90 % of conventional SCC, and high level expression is associated with a poorer prognosis. Anti-EGFR therapies are commonly used to treat head and neck SCC. However, no studies have evaluated EGFR expression in SpCC. Cases of SpCC were retrieved from department files. The diagnosis required either a biphasic lesion with a squamous neoplastic component, or a purely spindle cell or pleomorphic tumor with immunohistochemical positivity for epithelial markers. EGFR immunohistochemistry was performed and was quantified in quartiles. Medical records were reviewed for clinical follow up information. EGFR was expressed in 21/30 (70 %) cases, including in the squamous component in 18/19 (95 %) and the spindle cell component in only 12/30 (40 %). Where the spindle cell component was positive, the intensity and distribution were lower than for the squamous component. Recurrent tumors were predominantly (80-90 %) of the spindle cell component, and had low (or absent) EGFR expression. Kaplan-Meier survival analysis showed no statistically significant differences in overall or disease free survival between the EGFR expressing and non-expressing groups (p = 0.414 and 0.19, respectively). SpCCs of the head and neck have a poor prognosis, and markedly reduced EGFR expression. EGFR-specific therapies may not be ideal for SpCC patients, which may lack EGFR expression, but further studies are needed.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/pathology , ErbB Receptors/biosynthesis , Head and Neck Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Disease-Free Survival , ErbB Receptors/analysis , Female , Head and Neck Neoplasms/mortality , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Squamous Cell Carcinoma of Head and Neck
2.
Nature ; 409(6818): 355-9, 2001 Jan 18.
Article in English | MEDLINE | ID: mdl-11201745

ABSTRACT

The mitotic checkpoint protein hsMad2 is required to arrest cells in mitosis when chromosomes are unattached to the mitotic spindle. The presence of a single, lagging chromosome is sufficient to activate the checkpoint, producing a delay at the metaphase-anaphase transition until the last spindle attachment is made. Complete loss of the mitotic checkpoint results in embryonic lethality owing to chromosome mis-segregation in various organisms. Whether partial loss of checkpoint control leads to more subtle rates of chromosome instability compatible with cell viability remains unknown. Here we report that deletion of one MAD2 allele results in a defective mitotic checkpoint in both human cancer cells and murine primary embryonic fibroblasts. Checkpoint-defective cells show premature sister-chromatid separation in the presence of spindle inhibitors and an elevated rate of chromosome mis-segregation events in the absence of these agents. Furthermore, Mad2+/- mice develop lung tumours at high rates after long latencies, implicating defects in the mitotic checkpoint in tumorigenesis.


Subject(s)
Anaphase , Calcium-Binding Proteins/metabolism , Carrier Proteins , Chromosome Aberrations , Fungal Proteins/metabolism , Genes, cdc , Lung Neoplasms/genetics , Animals , Antineoplastic Agents/pharmacology , Calcium-Binding Proteins/antagonists & inhibitors , Cell Cycle Proteins , Cells, Cultured , Chromosome Segregation , Fungal Proteins/antagonists & inhibitors , Gene Deletion , Humans , Karyotyping , Mad2 Proteins , Mice , Mitosis/genetics , Mitosis/physiology , Nocodazole/pharmacology , Nuclear Proteins , Tumor Cells, Cultured
3.
J Electron Microsc Tech ; 18(2): 91-105, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1886006

ABSTRACT

In the present study, we have optimized an immunocytochemical ultrastructural approach for in situ localization of newly synthesized DNA in unsynchronized as well as in synchronized human HeLa cells and in exponentially growing mouse P815 cells, which had incorporated bromodeoxyuridine (BrdU) during short pulses varying from 1 to 20 minutes. The incorporated BrdU was detected in hydrolyzed ultrathin cryosections or Lowicryl sections by means of a monoclonal antibody, revealed by secondary colloidal gold-labeled probes. The results demonstrate our ability to study, with high resolution and reproducibility, DNA replication during consecutive periods of the S-phase, which is monitored by the incorporation of tritiated thymidine. In addition, this approach allows one to perform a concomitant mapping of replicated DNA and various enzymes of the replisome.


Subject(s)
DNA Replication , DNA/ultrastructure , Immunohistochemistry/methods , Microscopy, Immunoelectron/methods , Animals , Antibodies , Cell Cycle/drug effects , Freezing , HeLa Cells , Humans , Mice , Thymidine/pharmacology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...